Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

Moore Kathleen N.; Martin Lainie P.; OMalley David M.; Matulonis Ursula A.; Konner Jason A.; Perez Raymond P.; Bauer Todd M.; Ruiz-Soto Rodrigo; Birrer Michael J.

首页> 外文期刊>Journal of Clinical Oncology >Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

【24h】

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

机译：mirvetuximab索拉维斯汀（IMGN853）的安全性和活性，叶酸受体α-靶向抗体 - 药物缀合物，铂抗性卵巢，输卵管或原发性腹膜癌：I阶段扩张研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2017年第10期|共8页
作者
Moore Kathleen N.; Martin Lainie P.; OMalley David M.; Matulonis Ursula A.; Konner Jason A.; Perez Raymond P.; Bauer Todd M.; Ruiz-Soto Rodrigo; Birrer Michael J.;
展开▼
作者单位

Univ Oklahoma Hlth Sci Ctr Oklahoma City OK USA;

Fox Chase Canc Ctr 7701 Burholme Ave Philadelphia PA 19111 USA;

Ohio State Univ James Canc Ctr Columbus OH 43210 USA;

Dana Farber Canc Inst Boston MA 02115 USA;

Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10021 USA;

Univ Kansas Fairway KS USA;

Sarah Cannon Res Inst Nashville TN USA;

ImmunoGen Waltham MA USA;

Massachusetts Gen Hosp Boston MA 02114 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study [J] . Moore Kathleen N., Martin Lainie P., OMalley David M., Journal of Clinical Oncology . 2017,第10期

机译：mirvetuximab索拉维斯汀（IMGN853）的安全性和活性，叶酸受体α-靶向抗体 - 药物缀合物，铂抗性卵巢，输卵管或原发性腹膜癌：I阶段扩张研究
2. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models [J] . Jose F. Ponte, Olga Ab, Leanne Lanieri, Neoplasia: an international journal for oncology research . 2016,第12期

机译：Mirvetuximab Soravtansine（IMGN853），一种叶酸受体靶向抗体-药物结合物，可增强卵巢癌模型中标准治疗药物的活性
3. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR alpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer [J] . Gynecologic Oncology: An International Journal . 2020,第2期

机译：mirvetuximab索拉维三月，叶酸受体α（frα） - 抗体化药物缀合物（ADC）与铂抗性卵巢癌患者组合的叶酸受体α（FRα）的IB研究
4. Safety and Activity of Mirvetuximab Soravtansine (IMGN853) a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate in Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer: A Phase I Expansion Study [O] . Kathleen N. Moore, Lainie P. Martin, David M. O’Malley, -1

机译：叶酸受体α靶向抗体-药物结合物Mirvetuximab Soravtansine（IMGN853）在抗铂类卵巢癌输卵管或原发性腹膜癌中的安全性和活性：I期扩展研究
5. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models [O] . Ponte Jose F., Ab Olga, Lanieri Leanne, 2016

机译：Mirvetuximab Soravtansine（IMGN853），一种叶酸受体靶向抗体-药物结合物，可增强卵巢癌模型中标准治疗药物的活性

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

摘要

著录项

相似文献

相关主题

期刊订阅